Clinical recommendations: drug-induced liver injuries in adults


DOI: https://dx.doi.org/10.18565/therapy.2020.5.52-76

Approved by the Russian scientific medical society of internal medicine (RNMSIM) and the Scientific Society of gastroenterologists of Russia (SSGR), 2019. Agreed by the Research board of the Ministry of Healthcare of the Russian Federation, 2020.
Keywords: Hy’s law, idiosyncrasy, drug-induced liver injuries, drug hepatotoxicity
Read entire article

Literature


  1. Yu Y.-C., Mao Y.-M., Chen C.-W. et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017; 11(3):221–41. doi: 10.1007/s12072-017-9793-2.

  2. Галимова С.Ф. Лекарственные поражения печени (часть 1). Трансплантология. 2011; 1: 13–21. [Galimova S.F. Drug-induced liver injuries (part I). Transplantologiya. 2011; 1: 13–21 (In Russ.)].

  3. Chalasani N.P., Hayashi P.H., Bonkovsky H.L. et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014, 109(7): 950–66. doi: 10.1038/ajg.2014.131.

  4. Bjornsson E.S. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015; 89(3): 327–34. doi: 10.1007/s00204-015-1456-2.

  5. Sim S.C., Ingelman-Sundberg M. Update on allele nomenclature for humancytochromes P450 and the human cytochrome P450 allele (CYP-allele) nomenclature database. Methods Mol Biol. 2013; 987: 251–59. doi: 10.1007/978-1-62703-321-3_21.

  6. Болезни печени и желчевыводящих путей. Под ред. В.Т. Ивашкина. М.: Издательский дом «М-Вести, 2002; 416 c. [Diseases of the liver and biliary tract. Ed. by Ivashkin V.T. M.: M-Vesti. 2002; 416 p. (In Russ.)].

  7. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990; 11(2): 272–76. doi: 10.1016/0168-8278(90)90124-a.

  8. Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol. 2001; 14(6): 611–50. doi: 10.1021/tx0002583.

  9. Ивашкин. В.Т., Барановский А.Ю., Райхельсон К.Л. с соавт. Лекарственные поражения печени (клинические рекомендации для врачей). М., 2019; 57 с. [Ivashkin V.T., Baranovsky A.Yu., Raykhelson K.L. et al. Drug-induced liver injuries (clinical guidelines for doctors). M. 2019; 57 p. (In Russ.)].

  10. Байкова И.Е., Никитин И.Г. Лекарственное поражение печени. РМЖ. 2009; 1: 4–10. [Baykova I.E., Nikitin I.G. Drug-induced liver injury. Russky meditsinsky zhurnal. 2009; 1: 4–10 (In Russ.)].

  11. Буеверов А.О. Лекарственные поражения печени. РМЖ. 2012; 3: 107. [Bueverov A.O. Drug-induced liver injuries. Russky meditsinsky zhurnal. 2012; 3: 107 (In Russ.)].

  12. Licata A. Adverse drug reactions and organ damage: The liver. Eur J Intern Med. 2016; 28: 9–16. doi: 10.1016/j.ejim.2015.12.017.

  13. Bjornsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014; 34(2): 115–22. doi: 10.1055/s-0034-1375953.

  14. Hillman L., Gottfried M., Whitsett M. et al. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury. Am J Gastroenterol. 2016; 111(7): 958–65. doi: 10.1038/ajg.2016.114.

  15. Hoofnagle J.H., Serrano J., Knoben J.E. et al. LiverTox: a website on drug-induced liver injury. Hepatology. 2013; 57(3): 873–74. doi: 10.1002/hep.26175.

  16. Yimin M. HepaTox: The professional networking platform for promoting clinical and translational research of drug-induced liver injury in China. Chin Hepatol. 2014; 8: 575–76 (article in Chinese).

  17. Райхельсон К.Л., Пальгова Л.К., Кондрашина Э.А. с соавт. Лекарственные поражения печени. Клинические рекомендации для врачей. СПб., 2017; 116 с. [Raykhelson K.L., Palgova L.K., Kondrashina E.A. et al. Drug-induced liver injuries. Clinical guidelines for doctors. SPb. 2017; 116 p. (In Russ.)].

  18. Chalasani N.P., Hayashi P.H., Bonkovsky H.L. et al. ACG clinical guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014; 109(7): 950–66; quiz 967. doi: 10.1038/ajg.2014.131.

  19. Полунина Т.Е. Лекарственные поражения печени. РМЖ. Медицинское обозрение. 2018; 7-1: 7–12. [Polunina T.E. Drug-induced liver injuries. Russky meditsinsky zhurnal. Meditsinskoe obozrenie. 2018; 7-1: 7–12 (In Russ.)].

  20. Методические рекомендации по применению Vision International people group для оптимизации рациона питания и поддержания здоровья человека. М., 2010; 296 с. [Guidelines for the use of Vision International People Group on optimization of diet and human health consumption. M., 2010; 296 p. (In Russ.)].

  21. Aithal G.P., Watkins P.B., Andrade R.J. et al. Case definition and phenotype standardization in drug-induced liver injury. Review. Clin Pharmacol Ther. 2011; 89(6): 806–15. doi: 10.1038/clpt.2011.58.

  22. Drug-induced liver injury. By ed. Rodes J., Benhamou J.P., Blei A.T. et al. Textbook of hepatology: from basic science to clinical practice. 3rd ed. Blackwell Publishing. 2007; pp. 1211–77.

  23. Клинические рекомендации по коррекции гепатотоксичности индуцированной противоопухолевой химиотерапией. М., 2014. [Clinical guidelines on the correction of hepatotoxicity induced by antitumor chemotherapy. M., 2014 (In Russ.)].

  24. Матвеев А.В. Гепатопротекторы. Анализ международных исследований по препаратам группы лекарств для печени. Симферополь: ИТ «АРИАЛ», 2013; с. 382. [Matveev A.V. Hepatoprotectors. Analysis of international studies on drugs for the liver drug group. Simferopol: ARIAL. 2013; p. 382 (In Russ.)].

  25. Tsai J.H., Liu J.Y., Wu T.T. et al. Effects of silymarin on the resolution of liver ibrosis induced by carbon tetrachloride in rats. J Viral Hepat. 2008; 15(7): 508–14. doi: 10.1111/j.1365-2893.2008.00971.x.

  26. Santini D., Vincenzi B., Massacesi C. et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res. 2003; 23(6D): 5173–79.

  27. Лазебник Л.Б., Голованова Е.В., Алексеенко С.А. с соавт. Российский консенсус «Гипераммониемии у взрослых». Экспериментальная и клиническая гастроэнтерология. 2019; 12: 3–23. [Lazebnik L.G., Golovanova E.V., Alekseenko S.A. et al. Russian Consensus «Hyperammonemia in Adults». Eksperimental'naya i klinicheskaya gastroenterologiya. 2019; 12: 3–23 (In Russ.)]. doi: 10.31146/1682-8658-ecg-172-12-3-23.

  28. Beuers U., Boberg K.M., Chapman R.W. et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51(2): 237–67. doi: 10.1016/j.jhep.2009.04.009.

  29. Nathwani R.A., Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis. 2006; 10(2): 207–17, vii. doi: 10.1016/j.cld.2006.05.009.

  30. Лазебник Л.Б., Звенигородская Л.А., Морозов И.А., Шепелева С.Д. Клинико-морфологические изменения печени при атерогенной дислипидемии и при лечении статинами. Терапевтический архив. 2003; 8: 51–55. [Lazebnik L.G., Zvenigorodskaya L.A., Morozov I.A., Shepeleva S.D. Clinical and morphological changes in the liver with atherogenic dyslipidemia and with statins. Terapevtichesky arkhiv. 2003; 8: 51–55 (In Russ.)].

  31. Звенигородская Л.А., Лазебник Л.Б., Черкашова Е.А., Ефремов Л.И. Статиновый гепатит. Трудный пациент. 2009; 4–5: 44–49. [Zvenigorodskaya L.A., Lazebnik L.G., Cherkashova E.A., Efremov L.I. Statin Hepatitis. Trudny patsient. 2009; 4–5: 44–49 (In Russ.)].

  32. Liu X., Li X. An observation of essentiale’s efects on the liver protection during the medical treatment of tuberculosis. J Clin Pulm Med. 2002; 7(1): 18–19.

  33. Gurevich V., Bondarenko B., Gundermann K.J. Polyunsaturated phospholipids increase the hypolipidemic effect of lovastatin. Eur J Int Med. 1997; 8: 13–18.

  34. Горецкая М.В., Шейбак В.М. Гепатопротекторные свойства таурина при интоксикации парацетамолом. Известия Национальной академии наук Белоруссии. 2013; 3: 96–101. [Goretskaya M.V., Sheybak V.M. Hepatoprotective properties of taurine with acetaminophen intoxication. Izvestiya Natsional'noy akademii nauk Belorussii. 2013; 3: 96–101 (In Russ.)].

  35. Королева М.В. Возможности патогенетической терапии лекарственного поражения печени при туберкулезе. Журнал инфектологии. 2014; 3: 56–61. [Koroleva M.V. Possibility of pathogenetic therapy drug-induced liver injury in tuberculosis. Zhurnal infektologii. 2014; 3: 56–61 (In Russ.)].

  36. Ших Е.В., Сизова О.С., Махова А.А. Возможности применения гепатопротекторов в комбинированной терапии онихомикозов. РМЖ. 2014; 6: 1–6. [Shikh E.V., Sizova O.S., Makhova A.A. Possibilities of using hepatoprotectors in combination therapy of onychomycosis. Russky meditsinsky zhurnal. 2014; 6: 1–6 (In Russ.)].

  37. Пальцев А.И., Еремина А.А., Торгашов М.Н. Гепатозащитная роль гидролизата плаценты лаеннека в лечении больных с вирусно-паразитарными заболеваниями печени. Экспериментальная и клиническая гастроэнтерология. 2016; 11: 94–99. [Paltsev A.I., Yeremenko A.A., Torgashov M.N. Hepatoprotective role of placenta hydrolisat – laennec in the treatment of patients with viral and parasitic liver diseases. Eksperimental'naya i klinicheskaya gastroenterologiya. 2016; 11: 94–99 (In Russ.)].

  38. Минушкин О.Н., Максимов В.А., Пальцев А.И. с соавт. Рекомендации НОГР по применению гидролизата человеческой плаценты при заболеваниях печени. Экспериментальная и клиническая гастроэнтерология. 2016; 12: 75–77. [Minushkin O.N., Maksimov V.A., Paltsev A.I. et al. SSGR recommendations for the use of human placenta hydrolysate in liver diseases. Eksperimental'naya i klinicheskaya gastroenterologiya. 2016; 12: 75–77 (In Russ.)].

  39. Минушкин О.Н., Масловский Л.В., Зверков И.В. с соавт. «Лаеннек» в лечении некоторых заболеваний печени. Эффективная фармакотерапия. 2008; 1: 30–34. [Minushkin O.N., Maslovsky L.V., Zverkov I.V. et al. Laennec in the treatment of certain liver diseases. Effektivnaya farmakoterapiya. 2008; 1: 30–34 (In Russ.)].

  40. Громова О.А., Торшин И.Ю., Минушкин О.Н. с соавт. Об эффективности и молекулярных механизмах действия препарата «Лаеннек» в лечении патологических состояний печени, связанных с отложением железа в печени. Дело жизни. 2015; 1: 44–51. [Gromova O.A., Torshin I.Yu., Minushkin O.N. et al. On the effectiveness and molecular mechanisms of action of the drug Laennec in the treatment of pathological conditions of the liver associated with the deposition of iron in the live. Delo zhizni. 2015; 1: 44–51 (In Russ.)].

  41. Еремина Е.Ю. Патология органов пищеварительной системы у беременных. Lambert Academic Publishing. Германия. 2011. [Eremina E.Yu. Pathology of the digestive system in pregnant women. Lambert Academic Publishing. Germany. 2011 (In Russ.)].

  42. Ткачева О.Н., Бевз А.Ю., Ушкалова Е.А. с соавт. Первое всероссийское фармакоэпидемиологическое исследование «Эпидемиология использования лекарственных средств у беременных»: основные результаты. Акушерство и гинекология. 2011; 4: 112–117. [Tkacheva O.N., Bevz A.Yu., Ushkalova E.A. et al. The first All-Russian pharmacoepidemiological study «Epidemiology of drug use in pregnant women»: basic results. Akusherstvo i ginekologiya. 2011; 4: 112–117 (In Russ.)].

  43. Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. URL: http://www.fda.gov/cder/guidance/6695 dft.htm.

  44. Marschall H.U., Wagner M., Zollner G., Trauner M. Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. Mol Pharm. 2007; 4(6): 895–910. doi: 10.1021/mp060133c.

  45. Bjornsson E., Jerlstad P., Bergqvist A., Olsson R. Fulminant drug–induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005; 40(9): 1095–101. doi: 10.1080/00365520510023846.

  46. Еремина Е.Ю., Герасименко А.В., Герасименко И.В. Лекарственные поражения печени у беременных. Медицинский альманах. 2013; 1: 55–59. [Eremina E.Yu., Gerasimenko A.V., Gerasimenko I.V. Drug-induced liver injuries in pregnant women. Meditsinsky al'manakh. 2013; 1: 55–59 (In Russ.)].


About the Autors

Leonid B. Lazebnik, MD, professor, professor of the Department of outpatient therapy of A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia, President of the Scientific Society of Gastroenterologists of Russia, Vice-President of the Russian Scientific Medical Society of Internal Medicine. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (985) 920-83-42. Email: leonid.borisl@gmail.com

Back to Content

Бионика Медиа